Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: Results from a two-stage, phase IB study

Journal of Clinical Oncology

Volumn 32, Issue 17, 2014, Pages 1782-1791

  Salar, Antonio ^a   Avivi, Irit ^b   Bittner, Beate ^d   Bouabdallah, Reda ^e   Brewster, Mike ^f   Catalani, Olivier ^d   Follows, George ^g   Haynes, Andrew ^h   Hourcade Potelleret, Florence ^d   Janikova, Andrea ⁱ   Larouche, Jean François ^j   McIntyre, Christine ^f   Pedersen, Michael ^k   Pereira, Juliana ^l   Sayyed, Pakeeza ^d   Shpilberg, Ofer ^c   Tumyan, Gayane ^m  

^a HOSPITAL DEL MAR   (Spain)

^b RAMBAM MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e INSTITUT PAOLI CALMETTES   (France)

^f ROCHE PRODUCTS LTD   (United Kingdom)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^h NOTTINGHAM CITY HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^j LAVAL UNIVERSITY   (Canada)

^k GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^l UNIVERSITY OF SÃO PAULO   (Brazil)

^m N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB;

ADULT; ANAPHYLAXIS; AREA UNDER THE CURVE; ARTICLE; CANCER REGRESSION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYTOKINE RELEASE SYNDROME; DOSE CALCULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MYALGIA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TUMOR LYSIS SYNDROME; XEROSTOMIA;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED;

EID: 84905836916     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.52.2631     Document Type: Article

References (36)

1. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002 (Pubitemid 34438862)
2. Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005 (Pubitemid 41742196)
3. Marcus R, Imrie K, Solal-Celigny P, et al: Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26:4579-4586, 2008
4. Hallek M, Fischer K, Fingerle-Rowson G, et al: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 376:1164-1174, 2010
5. Salles G, Seymour JF, Offner F, et al: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. Lancet 377:42-51, 2011
6. Dreyling M, Ghielmini M, Marcus R, et al: Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 22:vi59-vi63, 2011
7. Ghielmini M, Vitolo U, Kimby E, et al: ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: Diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol 24:561-576, 2013
8. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas, version 1.2014. http://www.nccn.org/ professionals/physician-gls/pdf/nhl.pdf
9. Vogel WH: Infusion reactions: Diagnosis, assessment, and management. Clin J Oncol Nurs 14:E10-E21, 2010
10. Salar A, Bouabdallah R, McIntyre C, et al: A two-stage phase Ib study to investigate the pharmacokinetics, safety and tolerability of subcutaneous rituximab in patients with follicular lymphoma as part of maintenance treatment. Blood 116, 2010 (abstr 2858)
11. Bookbinder LH, Hofer A, Haller MF, et al: A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release 114:230-241, 2006 (Pubitemid 44291844)
12. Frost GI: Recombinant human hyaluronidase (rHuPH20): An enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv 4:427-440, 2007
13. Thomas JR, Wallace MS, Yocum RC, et al: The INFUSE-Morphine study: Use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness. J Pain Symptom Manage 38:663-672, 2009
14. Harb G, Lebel F, Battikha J, et al: Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers. Curr Med Res Opin 26:279-288, 2010
15. Ismael G, Hegg R, Muehlbauer S, et al: Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): A phase 3, open-label, multicentre, randomised trial. Lancet Oncol 13:869-878, 2012
16. Pivot X, Gligorov J, Müller V, et al: Patient preference for subcutaneous versus intravenous adjuvant trastuzumab: Results of the PrefHer Study. 13th St Gallen International Breast Cancer Conference, St Gallen, Switzerland, March 13-16, 2013
17. Stilgenbauer S, Zenz T, Winkler D, et al: Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: Clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 27:3994-4001, 2009
18. Bai S, Jorga K, Xin Y, et al: A guide to rational dosing of monoclonal antibodies. Clin Pharmacokinet 51:119-135, 2012
19. Reff ME, Carner K, Chambers KS, et al: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445, 1994 (Pubitemid 24030569)
20. Velagapudi R, Noertershauser P, Awni W, et al: Bioavailability of adalimumab following subcutaneous injections in rheumatoid arthritis patients. Clin Pharmacol Ther 77:P84, 2005
21. Yin A, Li J, Hurst D, et al: Population pharmacokinetics (PK) and association of PK and clinical outcomes of rituximab in patients with non-Hodgkin's lymphoma. J Clin Oncol 28, 2010 (suppl; abstr e13108)
22. O'Brien SM, Kantarjian H, Thomas DA, et al: Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19:2165-2170, 2001 (Pubitemid 32366970)
23. Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927-1932, 1998 (Pubitemid 28446681)
24. Coiffier B, Thieblemont C, Van Den Neste E, et al: Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 116:2040-2045, 2010
25. Keating M, O'Brien S: High-dose rituximab therapy in chronic lymphocytic leukemia. Semin Oncol 27:86-90, 2000 (Pubitemid 32164600)
26. Lundin J, Kimby E, Björkholm M, et al: Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100:768-773, 2002 (Pubitemid 34832599)
27. Forstpointner R, Unterhalt M, Dreyling M, et al: Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108:4003-4008, 2006 (Pubitemid 44920177)
28. Ghielmini M, Schmitz SF, Cogliatti SB, et al: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 103:4416-4423, 2004 (Pubitemid 38745964)
29. Hochster H, Weller E, Gascoyne RD, et al: Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: Results of the randomized phase III ECOG 1496 Study. J Clin Oncol 27:1607-1614, 2009
30. van Oers MH, Klasa R, Marcus RE, et al: Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood 108:3295-3301, 2006 (Pubitemid 44794222)
31. van Oers MH, Van Glabbeke M, Giurgea L, et al: Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: Long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 28:2853-2858, 2010
32. Cartron G, Watier H, Golay J, et al: From the bench to the bedside: Ways to improve rituximab efficacy. Blood 104:2635-2642, 2004 (Pubitemid 39434941)
33. Davies A, Merli F, Mihaljevic B, et al: Pharmacokinetics (PK), safety and overall response rate (ORR) achieved with subcutaneous (SC) administration of rituximab in combination with chemotherapy were comparable to those achieved with intravenous (IV) administration in patients (pts) with follicular lymphoma (FL) in the first-line setting: Stage 1 results of the phase III SABRINA study (BO22334). Presented at the 54th American Society of Hematology Annual Meeting, Atlanta, GA, December 8-11, 2012 (abstr 1629)
34. Moreau P, Coiteux V, Hulin C, et al: Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica 93:1908-1911, 2008
35. Moreau P, Pylypenko H, Grosicki S, et al: Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study. Lancet Oncol 12:431-440, 2011
36. De Cock E, Kritikoi P, Tao S, et al: Time and resource savings with rituximab subcutaneous (SC) injection vs rituximab intravenous (IV) infusion: First results from a time and motion study (T&M). Presented at the 18th European Hematology Association Annual Congress, Stockholm, Sweden, June 13-16, 2013 (abstr 4326)